Read More

CytoSorbents Reports Outcomes From A Randomized Controlled Trial Using CytoSorb Blood Purification During Heart Transplant, Recently Published In The European Society Of Cardiology Journal, ESC Heart Failure

Better hemodynamic stability and lower rates of post-operative shock Patients in the CytoSorb group had lower median Vasoactive-Inotropic Scores (27.2 [14.6–47.7] vs. 41.9 [22.4–63.2], p=0.046) and

CTSO

Read More

Cholesterol Player NewAmsterdam Pharma’s Obicetrapib Is A Potential Blockbuster In Cardiovascular Market: Bullish Analyst Says

Piper Sandler's coverage on NewAmsterdam Pharma and its clinical-stage therapy, Obicetrapib, a potent CETP inhibitor targeting cardiovascular health. With a unique mechanism, superior efficacy, and market potential, Piper gives an Overweight rating and a $37 price target.

NAMS

Read More

Cytokinetics’ Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst

Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed as a distinctive therapy for Hypertrophic Cardiomyopathy.

AZN